Axonics, Outset lead medtech space on Deloitte’s list of fastest growing companies

Deloitte today released its “North America Technology Fast 500” list of growing companies, including a handful of medtech firms.

The list, which ranking of the fastest-growing North American companies across a range of sectors, included several “Life Sciences” outfits. Immunology company Vir Biotechnology led the way in first place on the list.

Axonics (Nasdaq:AXNX) represented the highest-ranked medical device company at No. 4. According to Deloitte, the company registered 25,401% growth over a three-year period. Axonics reported $180.3 million in revenue in fiscal 2021, compared to $707,000 in fiscal 2018.

The company topped last year’s version of the list. Axonics develops novel products for adults with bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy-to-use, safe, clinically effective therapy. The compa…

Read more
  • 0

Pulmatrix completes patient dosing for inhaled migraine treatment

iSperse technology. [Image from Pulmatrix]Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment.

Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the fourth quarter of this year.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Pulmatrix completes $40M offering, updates product pipeline timetable

Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million.

Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway.

Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes a Phase 1b study for its PUR1800 therapeutic, a Phase 1/2 study for PUR3100 and a Phase 2b study for Pulmazole.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0